Fisher Asset Management LLC Sells 19,824 Shares of Prestige Consumer Healthcare Inc. $PBH

Fisher Asset Management LLC reduced its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 6.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 273,885 shares of the company’s stock after selling 19,824 shares during the period. Fisher Asset Management LLC owned about 0.58% of Prestige Consumer Healthcare worth $16,896,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bayforest Capital Ltd bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at approximately $29,000. Barrow Hanley Mewhinney & Strauss LLC grew its position in shares of Prestige Consumer Healthcare by 106.8% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after acquiring an additional 283 shares during the period. Geneos Wealth Management Inc. grew its position in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares during the period. Torren Management LLC bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at approximately $35,000. Finally, Danske Bank A S bought a new position in shares of Prestige Consumer Healthcare during the 3rd quarter valued at approximately $37,000. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Stock Up 0.4%

Shares of NYSE:PBH opened at $48.23 on Thursday. The firm has a fifty day moving average price of $55.16 and a two-hundred day moving average price of $60.64. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $87.12. The company has a market cap of $2.28 billion, a price-to-earnings ratio of 12.34, a PEG ratio of 1.54 and a beta of 0.40.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm had revenue of $281.62 million during the quarter, compared to the consensus estimate of $293.64 million. During the same period in the previous year, the business earned $1.32 earnings per share. The firm’s revenue for the quarter was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on PBH. Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Jefferies Financial Group cut their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Finally, Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and a consensus target price of $70.75.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).